Lead Product(s): mRNA-6231
Therapeutic Area: Immunology
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2020
Moderna has entered a new autoimmune therapeutic area with two additional development candidates, mRNA-6231 and mRNA-6981. Company to expand pipeline of innovative vaccines in the near term.